StreetAlpha.app
Home › Stocks › IBIO

iBio, Inc. (IBIO)

$0.80
▼ −0.11%
LAST CLOSE · NOV 20

iBio is a clinical stage biotech developing AI designed antibody drugs for obesity and related heart and lung diseases. It last closed at $0.80 on Nov 20, down 0.11% on the day. The next earnings report for IBIO is expected around Tue, Feb 9, 2027, after the close. For the quarter ended Sep 2026, IBIO reported EPS of -$0.05 on revenue of $1.1M, with revenue up 975.0% from a year ago. Over its last 8 reports the stock moved an average of 4.2% the session after earnings. Over the last 12 months IBIO insiders bought $98K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is IBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IBIO.

Key Stats

Last 12 months
Results
Revenue
$1.1M
+115.0% vs a year ago
Net income
−$34.9M
−3244.2% margin
EPS (diluted)
−$0.26
Free cash flow
−$27.6M
−2566.3% margin
Valuation
Market cap
$56.4M
70.5M shares
P/E
–
No P/E while losing money
Price to sales
52.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$45.4M
At Sep 30
Shareholder equity
$78.6M
Shares outstanding
70.5M
At Nov 10
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $1.9M$1.9MFY2022FY2023: $0$0FY2023FY2024: $225K$225KFY2024FY2025: $400K$400KFY2025FY2026: $100K$100KFY2026

From IBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 9
Estimated date · After the close
Reported EPS
-$0.05
Quarter ended Sep 2026
Year ago EPS
-$0.11
Same quarter last year
Revenue
$1.1M
+975.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.48Dec '24Mar 2025: -$0.49Mar '25Jun 2025: -$1.64Jun '25Sep 2025: -$0.11Sep '25Dec 2025: -$0.09Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.27Jun '26Sep 2026: -$0.05Sep '26Latest -$0.05
Revenue by quarter
Dec 2024: $200,000Dec '24Mar 2025: $0Mar '25Jun 2025: $200,000Jun '25Sep 2025: $100,000Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $1.1MSep '26Latest $1.1M
How IBIO moved after its last 8 reports
Average move the session after a report ±4.2%
Nov 10, 2026After the close+5.7%
Aug 28, 2026Time not announced−2.9%
May 12, 2026After the close−3.7%
Feb 10, 2026After the close−2.6%
Nov 12, 2025After the close−8.0%
Aug 18, 2025After the close−1.3%
May 2, 2025Time not announced−1.9%
Feb 10, 2025After the close−7.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IBIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IBIO

Technical Analysis

IBIO · as of the Nov 20 close · updated each morning
Downtrend

The stock sits between its 20 and 50 day averages. It is 98% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $0.80, and the nearest resistance the swing high (Nov 11) at $0.83.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 9.5%/day
Key levels
$3.8252 week high+377.5%
$1.58200 day average+97.5%
$1.17100 day average+46.2%
$0.9350 day average+16.3%
$0.83Pivot R1+3.7%
$0.83Swing high (Nov 11)+3.7%
$0.80Pivot+0.0%
$0.80Last close
$0.7820 day average−2.5%
$0.77Pivot S1−3.7%
$0.73Swing low (Oct 14)−8.8%
$0.6852 week low−15.0%
Indicators
RSI (14)47.80Middle of its rangeNeutral
MACD-0.03Above its signal lineBullish
Stochastic73.2Middle of its rangeNeutral
ADX (14)20.4Weak trend
Williams %R-35.2Oversold below −80, overbought above −20Neutral
CCI (20)48.5Oversold below −100, overbought above 100Neutral
Rate of change+8.3%Change over 10 sessionsBullish
ATR (14)$0.08Typical daily range, 9.5% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for IBIO

What happened before

See how IBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IBIOHow many large options trades hit IBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲27 buying vs 17 selling
  • ▲Held by funds +4.0 pts
  • ▲Funds holding +7
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6255+12.7%
In funds' top 1000–
Held by funds53.3%49.3%+4.0 pts
New / increased11 / 1615 / 22−27.0%
Reduced / sold out13 / 49 / 12−19.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IBIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$98K3 buys · 3 insiders
Sold$00 sales · 0 insiders
Cluster buy: 3 insiders bought $98K between Mar 19 and Mar 26.
2026-03 bought $98KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 26Marc BanjakChief Legal OfficerBuy13,934$1.65$23K
Mar 19Martin BrennerSee RemarksBuy12,336$2.02$25K
Mar 19Felipe DuranCFOBuy24,835$2.02$50K
Jan 10, 2025Gary SenderDirectorBuy9,191$2.72$25K
Jan 10, 2025Antonio Bernardino Guimaraes ParadaDirectorBuy183,823$2.72$500K
Jan 10, 2025William D ClarkDirectorBuy1,838$2.72$5K
Every insider buy and sale for IBIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IBIO insider trades →

From SEC Form 4 filings by IBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBIO is in one of them and how their past IBIO trades turned out.

IBIO in the AI portfolios
Loading…

IBIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IBIO in an article yet. Here's the latest on the wider market.

IBIO in the news

About iBio

iBio is a biotechnology company that uses artificial intelligence to design antibody drugs. Its work focuses on obesity and related heart and lung conditions, including pulmonary hypertension linked to heart failure. Its lead candidate, IBIO-600, is in a Phase 1 clinical trial, and other candidates are in earlier preclinical development. No products are approved yet, so its intended customers are patients with these conditions and the clinicians who treat them. The company is based in New York and conducts its research at a laboratory in San Diego.

Headquarters
New York, NY